Please try another search
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Timothy Mark Dyer | 53 | 2002 | Co-Founder, CEO & Director |
Vincent Lawton | 72 | 2009 | Independent Chairman of the Board |
Isaac Manke | 45 | 2018 | Independent Director |
Mark F. Bear | - | - | Scientific Advisory Board Member |
Peter R. Bernstein | - | - | Scientific Advisory Board Member |
Jason R. Nunn | 52 | 2018 | Independent Director |
Roger G. Mills | 65 | 2016 | Chief Medical Officer & Director |
Raymond G. Hill | 78 | 2015 | Non-Executive Director |
Bernhard Bettler | - | - | Member of Scientific Advisory Board |
Darryle D. Schoepp | - | 2020 | Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review